Read what they said in thier report. Vertex also today provided an update on ongoing and planned clinical trials for its broad pipeline of potential new treatments for hepatitis C, cystic fibrosis, rheumatoid arthritis, epilepsy and influenza. In addition to INCIVEK, Vertex has seven other potential medicines in clinical development
Totally agree about being undervalued at this point. We need to get rid of analysts like Adam Feuerstein and The Street.com with comments such as the one below with potentially stronger Hep C drugs coming closer to approval. Closer being most likely 2 years down the road. Gives us all a break Adam and take a more realistic look at the whole picture. VRTX is currently the Secretariat of Hep C with an excellent pipeline of new drugs. I'll stay long VRTX and you can buy JNJ, VRUS and ABT. I'll be waiting for you at the finish line.
Analysts expect a lot from Incivek: $793 million in 2011 sales jumping to $2 billion in 2012, according to an average of analyst estimates compiled by but not endorsed by Vertex.
Incivek competes against Merck's(MRK_) Victrelis today but newer, potentially stronger hepatitis C drugs from Johnson & Johnson(JNJ_), Pharmasset(VRUS_) and Abbott(ABT_), among others, are moving closer to approval.